USP9X and glioblastoma: Median immune reactivity score (IRS) of Mcl-1 increased from 0.92±0.40 (95% from 0.13 to 1.71, n=38) in grade III astrocytoma to 5.23±0.43 (95% from 4.38 to 6.08, n=33) in glioblastoma, whereas IRS of USP9x increased from 3.24±0.42 (95% from 2.39 to 4.08, n=42) in astrocytoma to 4.91±0.41 (95% from 4.10 to 5.73, n=45) in glioblastoma.